Clinical Trial Detail

NCT ID NCT03316573
Title A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lymphoma

interdigitating dendritic cell sarcoma

diffuse large B-cell lymphoma

follicular dendritic cell sarcoma

histiocytic and dendritic cell cancer

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.